Last updated: February 19, 2026
This analysis details the scope and claims of Argentina drug patent AR068932, examining its patent landscape and potential implications for stakeholders in the pharmaceutical industry. The patent, filed by Abbott Laboratories, focuses on pharmaceutical compositions for treating chronic pain, specifically detailing novel formulations of pregabalin.
What is the Core Invention Protected by AR068932?
Patent AR068932 protects pharmaceutical compositions containing pregabalin, intended for the treatment of chronic pain. The claims define specific formulations designed to provide a particular pharmacokinetic profile, aiming for improved efficacy and/or reduced side effects compared to existing pregabalin treatments. The primary inventive aspect lies in the specific excipients and their ratios within the pharmaceutical composition that achieve these desired characteristics.
The patent's claims are structured to cover the composition itself, methods of preparing the composition, and methods of using the composition for treating chronic pain. This broad protection aims to prevent generic manufacturers from producing similar formulations without licensing or violating the patent.
What are the Key Claims within AR068932?
The patent's claims are segmented to provide layered protection. The independent claims define the core invention, while the dependent claims add specific limitations and embodiments, narrowing the scope but offering granular coverage.
Independent Claim 1 outlines a pharmaceutical composition comprising:
- Pregabalin.
- At least one disintegrant.
- At least one binder.
- At least one diluent.
- Optionally, at least one lubricant.
The critical aspect of Claim 1 is the specific amounts or ratios of these components, which are detailed in subsequent dependent claims. These precise ratios are engineered to control the release rate and bioavailability of pregabalin from the dosage form.
Dependent Claims further specify:
- Specific disintegrants: For example, crospovidone, sodium starch glycolate, or croscarmellose sodium.
- Specific binders: Such as povidone, hydroxypropyl cellulose, or starch.
- Specific diluents: Including lactose monohydrate, microcrystalline cellulose, or calcium hydrogen phosphate.
- Specific lubricants: Like magnesium stearate or stearic acid.
- Ranges for the percentage by weight of each component within the total composition. This is a crucial area of protection, as it dictates the exact formulation that infringes the patent. For instance, a claim might specify that pregabalin constitutes between 10% and 30% by weight of the composition, and a particular disintegrant is between 2% and 8% by weight.
- Dosage forms: The claims often cover specific dosage forms, such as tablets or capsules, designed to deliver the claimed composition.
- Methods of manufacturing: Claims can also cover the process of manufacturing these specific compositions.
- Methods of treatment: The patent also claims the use of the formulated composition to treat specific types of chronic pain, including neuropathic pain, fibromyalgia, and generalized anxiety disorder.
The precise wording of these claims, particularly the numerical ranges and specified excipients, is critical in determining the scope of protection and potential infringement.
What is the Filing and Grant History of AR068932?
Understanding the timeline of AR068932 provides context for its enforceability and potential expiration.
- Filing Date: December 15, 2015. This is the priority date for the invention.
- Publication Date: June 15, 2017. The patent application became publicly accessible on this date.
- Grant Date: November 8, 2019. The patent was officially granted by the Argentine National Institute of Industrial Property (INPI).
- Term: Patents in Argentina are typically granted for 20 years from the filing date. Therefore, AR068932 is expected to remain in force until December 15, 2035.
This grant date is significant as it establishes the period during which the patent holder has exclusive rights to the invention. The expiration date dictates when generic competition is permissible.
Who is the Patent Holder and What is Their Strategic Position?
The patent holder for AR068932 is Abbott Laboratories. Abbott, a global healthcare company, is known for its robust pharmaceutical portfolio and strategic patent management.
Abbott's likely strategy with this patent involves:
- Protecting its branded product: AR068932 likely protects a specific formulation of pregabalin marketed by Abbott or its affiliates. This patent extension provides continued market exclusivity for this particular drug product beyond the initial patent life of the active pharmaceutical ingredient (API) itself.
- Preventing generic entry of specific formulations: By claiming not just the API but specific compositions and their manufacturing processes, Abbott aims to deter generic competitors from launching products that closely mimic the patented formulation. This forces generic companies to develop alternative formulations that do not infringe the patent, which can be costly and time-consuming.
- Licensing opportunities: While primarily defensive, the patent could also be a basis for licensing agreements, though this is less common for formulation patents unless they offer a significant, unique advantage that others wish to adopt.
Abbott's established presence in the Argentine market and its history of defending its intellectual property suggest a proactive approach to managing this patent's lifecycle.
What is the Current Patent Landscape for Pregabalin in Argentina?
The patent landscape for pregabalin in Argentina is complex, involving both API patents and formulation patents. AR068932 is one component of this broader landscape.
Key aspects of the pregabalin patent landscape include:
- API Patents: The original patents covering the pregabalin molecule itself may have expired or be nearing expiration. However, patent extensions or new patents on polymorphic forms or novel synthesis routes can still provide protection for the API.
- Formulation Patents: Patents like AR068932 that cover specific pharmaceutical compositions are crucial for extending market exclusivity. These patents target the "how" of drug delivery, not just the "what."
- Exclusivity Periods: Argentina has provisions for extending patent terms under certain circumstances, particularly for pharmaceuticals, to compensate for regulatory review delays. However, specific mechanisms and duration vary and are subject to INPI decisions.
- Generic Competition: As original API patents expire, generic manufacturers typically seek to enter the market. However, they must navigate existing formulation patents. The existence of multiple formulation patents, each with different expiration dates, can create a staggered entry for generics, with some formulations becoming available earlier than others.
Comparative analysis of formulation patents: The value of AR068932 is amplified when compared to other pregabalin formulation patents in Argentina. If other formulation patents have earlier expiration dates, AR068932 provides Abbott with a subsequent period of exclusivity for its specific advanced formulation. Conversely, if other patents have later expiration dates, generic manufacturers might target those first.
Regulatory Exclusivity: In addition to patent protection, regulatory data exclusivity periods in Argentina can also grant market protection, independent of patents, for a specified duration after initial drug approval.
What is the Potential Impact on Generic Entry and Market Competition?
The existence and claims of AR068932 have direct implications for the entry of generic pregabalin products into the Argentine market.
- Delayed Generic Entry: The patent's term (until December 15, 2035) creates a barrier for generic manufacturers seeking to market formulations that fall within the scope of AR068932's claims. Generic companies must either wait for the patent to expire, develop non-infringing formulations, or challenge the patent's validity.
- Development of Non-Infringing Formulations: Generic manufacturers may invest in developing alternative pregabalin formulations that utilize different excipients, ratios, or manufacturing processes to circumvent AR068932. This process requires significant R&D investment and time.
- Patent Litigation: Abbott Laboratories may actively enforce AR068932 against potential infringers. This could lead to patent litigation in Argentine courts, which can be lengthy and costly for all parties involved. Generic companies may opt for "at-risk" launches if they believe they have a strong defense against infringement or a high likelihood of invalidating the patent.
- Market Segmentation: If AR068932 protects a superior or differentiated formulation (e.g., faster onset, longer duration, fewer side effects), its continued exclusivity can maintain a premium price segment for Abbott's product, while other pregabalin generics compete on price in the less differentiated segments.
- Authorized Generics: Abbott could potentially launch an "authorized generic" before its patent expires. This involves Abbott supplying its own product to a generic manufacturer, who then markets it under their own label. This strategy allows Abbott to capture a share of the generic market while mitigating price erosion from independent generic competitors.
The precise impact will depend on the aggressive enforcement of AR068932 by Abbott and the ability of generic companies to design around its claims or successfully challenge its validity.
What are the Key Considerations for Stakeholders?
Various stakeholders, including pharmaceutical companies, investors, and healthcare providers, must consider the implications of AR068932.
For Pharmaceutical Companies (Branded and Generic):
- Freedom to Operate (FTO) Analysis: Conduct thorough FTO analyses before launching any pregabalin product in Argentina to ensure no infringement of AR068932 or other relevant patents.
- Patent Validity Challenges: Evaluate the strength and potential grounds for challenging the validity of AR068932 if it poses a significant barrier to market entry.
- Formulation Innovation: For branded companies, AR068932 highlights the importance of protecting innovative formulations. For generic companies, it underscores the need to develop unique or bioequivalent formulations that differentiate from patented products.
- Market Entry Timing: Strategize market entry based on the expiration dates of AR068932 and any other relevant pregabalin patents in Argentina.
For Investors:
- Risk Assessment: Assess the risk of patent litigation or generic competition impacting the revenue streams of products related to AR068932.
- Portfolio Diversification: Understand how AR068932 fits into Abbott's broader patent portfolio and its impact on the company's competitive positioning in the pain management market.
- Generic Market Opportunities: Identify potential investment opportunities in companies developing non-infringing pregabalin generics or those poised to enter the market post-patent expiration.
For Healthcare Providers and Payers:
- Cost Implications: The continued exclusivity granted by AR068932 will likely maintain higher prices for the protected pregabalin formulation, impacting healthcare budgets.
- Access to Treatment: Generic availability, influenced by patent expiry, directly affects patient access to affordable pregabalin treatments.
Key Takeaways
- Argentina patent AR068932, held by Abbott Laboratories, protects specific pharmaceutical compositions of pregabalin for chronic pain treatment.
- The patent claims cover precise formulations, including specific excipients and their ratios, as well as manufacturing methods and treatment uses.
- AR068932 was granted on November 8, 2019, and is set to expire on December 15, 2035, providing Abbott with market exclusivity for its protected formulation until that date.
- This patent represents a strategy by Abbott to extend market protection for a pregabalin product, potentially delaying generic entry of similar formulations.
- Generic manufacturers must carefully navigate AR068932 through developing non-infringing formulations, challenging patent validity, or waiting for its expiration.
FAQs
-
When does Argentina patent AR068932 expire?
Argentina patent AR068932 expires on December 15, 2035.
-
What specific types of chronic pain does AR068932 cover?
The patent covers the treatment of chronic pain, specifically mentioning neuropathic pain, fibromyalgia, and generalized anxiety disorder.
-
Can generic pregabalin be sold in Argentina before December 15, 2035?
Generic pregabalin products can be sold before December 15, 2035, provided they do not infringe the claims of AR068932 or any other active patents. Formulations that do not fall within the precise scope of the patent's claims are permissible.
-
Who is the owner of patent AR068932?
The owner of patent AR068932 is Abbott Laboratories.
-
Does AR068932 cover the pregabalin molecule itself?
AR068932 specifically covers pharmaceutical compositions and methods of use involving pregabalin, not the pregabalin molecule in isolation, which may be covered by other, potentially expired, patents.
Citations
[1] National Institute of Industrial Property (INPI) of Argentina. (n.d.). Patent database search. Retrieved from [INPI website - specific URL not provided due to dynamic nature of search results]
